文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

成人脓毒性休克:氢化可的松之外还需要加用氟氢可的松吗?一项更新的系统评价(贝叶斯网络Meta分析)及一项目标试验模拟观察性研究

Do We Need to Administer Fludrocortisone in Addition to Hydrocortisone in Adult Patients With Septic Shock? An Updated Systematic Review With Bayesian Network Meta-Analysis of Randomized Controlled Trials and an Observational Study With Target Trial Emulation.
PubMed 文献 · Crit Care Med · 2023-12-29
一句话结论与单用氢化可的松或安慰剂相比,氢化可的松联合氟氢可的松在成人脓毒性休克中降低短期死亡(OR 0.79,NNT 21),但证据确定性低、NNT范围宽,尚非定论。

该系统评价与贝叶斯网络Meta分析纳入19项研究共95,841例成人脓毒性休克患者,比较氢化可的松联合氟氢可的松、单用氢化可的松与安慰剂。主要终点为短期死亡(以28天或30天死亡为主,住院或ICU死亡为最近替代)。氢化可的松联合氟氢可的松较安慰剂短期死亡最低(OR 0.79;95%CrI 0.64-0.99;NNT 21,范围12-500;证据确定性低)。在三组累积排序曲线下面积中,联合组0.9469、单用氢化可的松组0.4542、安慰剂组0.0989。胃十二指肠出血或重叠感染未见明确增加,但高血糖风险增加(安慰剂 vs 联合组OR 0.53;安慰剂 vs 单用氢化可的松组OR 0.64;证据确定性极低)。作者认为联合方案改善短期生存且不良事件少,但证据确定性有限、NNT范围宽,需进一步大规模安慰剂对照RCT提供确凿证据。

要点

  • 在成人脓毒性休克中,氢化可的松联合氟氢可的松较安慰剂降低短期死亡(OR 0.79;95%CrI 0.64-0.99;NNT 21,范围12-500;证据确定性低)。
  • 累积排序曲线下面积:联合组0.9469 > 单用氢化可的松组0.4542 > 安慰剂组0.0989,联合方案排序最优。
  • 仅纳入RCT及使用氢化可的松每日200 mg剂量的研究,结果与总体一致。
  • 胃十二指肠出血或重叠感染未见明确增加,但高血糖风险增加(安慰剂 vs 联合组OR 0.53;安慰剂 vs 单用氢化可的松组OR 0.64;证据确定性极低)。
  • 作者认为联合方案改善短期生存且不良事件少,但证据确定性有限、NNT范围宽,需进一步大规模安慰剂对照RCT提供确凿证据。

适用人群与场景

  • 成人脓毒性休克患者;纳入RCT及采用目标试验模拟的观察性研究。

研究设计与关键结果

  • 研究类型:更新的系统评价与贝叶斯网络Meta分析,检索PubMed、Embase、Cochrane Library、ClinicalTrials.gov及其他相关网站至2023年8月31日。
  • 共纳入19项研究、95,841例患者;干预为氢化可的松联合氟氢可的松或单用氢化可的松,对照为安慰剂。
  • 主要终点短期死亡(以28天或30天死亡为主,住院或ICU死亡为最近替代):氢化可的松联合氟氢可的松较安慰剂OR 0.79(95%CrI 0.64-0.99),NNT 21(范围12-500),证据确定性低(基于信息性先验)。
  • 累积排序曲线下面积:氢化可的松联合氟氢可的松0.9469、单用氢化可的松0.4542、安慰剂0.0989。
  • 仅纳入RCT及使用氢化可的松每日200 mg剂量的研究,结果与总体一致。
  • 不良事件:胃十二指肠出血或重叠感染未见明确增加,但高血糖风险增加;安慰剂 vs 氢化可的松联合氟氢可的松OR 0.53,安慰剂 vs 单用氢化可的松OR 0.64,证据确定性极低。

证据类型、等级与局限

  • 证据类型:系统评价与贝叶斯网络Meta分析(含RCT及目标试验模拟观察性研究)。
  • 证据确定性:短期死亡结局为低确定性证据;高血糖相关比较为极低确定性证据。
  • 局限:证据确定性有限、NNT范围宽(12-500);作者指出需进一步大规模安慰剂对照RCT提供确凿证据。

对床旁实践的改变

  • 作者认为,在成人脓毒性休克中,氢化可的松联合氟氢可的松较单用氢化可的松或安慰剂改善短期生存且不良事件少。
  • 作者指出该发现因证据确定性有限、NNT范围宽而尚非定论,需进一步大规模安慰剂对照RCT提供确凿证据。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: This systematic review and Bayesian network meta-analysis evaluated the efficacy and safety of hydrocortisone combined with fludrocortisone or hydrocortisone alone, compared with placebo in adult patients with septic shock.

DATA SOURCES: By extending a prior Cochrane review, databases, including PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov , along with other relevant websites, were searched until August 31, 2023.

STUDY SELECTION: Randomized controlled trials (RCTs) and observational studies using target trial emulation were included.

DATA EXTRACTION: The primary outcome was short-term mortality with an emphasis on 28- or 30-day mortality as the main measure and in-hospital or ICU mortality as the nearest surrogate of this measure. Three of the most common adverse events, namely, gastroduodenal bleeding, superinfection, and hyperglycemia, were also considered.

DATA SYNTHESIS: A total of 19 studies involving 95,841 patients were included. Hydrocortisone plus fludrocortisone showed the lowest short-term mortality versus placebo (odds ratio [OR]: 0.79; 95% credible interval [CrI], 0.64-0.99; number needed to treat [NNT]: 21, range: 12-500; low certainty of evidence) in terms of informative priors. The surface under the cumulative ranking curve values for hydrocortisone plus fludrocortisone, hydrocortisone alone, and placebo were 0.9469, 0.4542, and 0.0989, respectively. Consistent results were observed in RCTs alone and those using a daily 200-mg dose of hydrocortisone. Although gastroduodenal bleeding or superinfection showed no clear increase, hyperglycemia risk increased. The ORs were 0.53 for placebo versus hydrocortisone plus fludrocortisone and 0.64 for placebo versus hydrocortisone alone, with very low certainty of evidence.

CONCLUSIONS: In adults with septic shock, hydrocortisone plus fludrocortisone improved short-term survival with minimal adverse events compared with hydrocortisone alone or placebo. However, these findings are not definitive due to the limited certainty of evidence and wide NNT range. Additional large-scale, placebo-controlled RCTs are needed to provide conclusive evidence.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Lai PC, Lai CH, Lai EC, et al. Do We Need to Administer Fludrocortisone in Addition to Hydrocortisone in Adult Patients With Septic Shock? An Updated Systematic Review With Bayesian Network Meta-Analysis of Randomized Controlled Trials and an Observational Study With Target Trial Emulation. Crit Care Med. 2023. PMID: 38156911. doi:10.1097/CCM.0000000000006161

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。